{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Novartis",
    "query": {
      "sponsor": "Novartis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Novartis&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T20:57:30.357Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05982886",
      "title": "Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1093,
      "start_date": "2021-01-15",
      "completion_date": "2021-04-01",
      "has_results": false,
      "last_update_posted_date": "2023-08-09",
      "last_synced_at": "2026-07-24T20:57:30.357Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05982886"
    },
    {
      "nct_id": "NCT00821977",
      "title": "Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Vildagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 338,
      "start_date": "2008-11",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-07-24T20:57:30.357Z",
      "location_count": 141,
      "location_summary": "Pell City, Alabama • Gilbert, Arizona • Mesa, Arizona + 116 more",
      "locations": [
        {
          "city": "Pell City",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00821977"
    },
    {
      "nct_id": "NCT02404441",
      "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Sell Lung Cancer (NSCLC)",
        "Triple Negative Breast Cancer",
        "Anaplastic Thyroid Cancer",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PDR001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 319,
      "start_date": "2015-04-27",
      "completion_date": "2020-07-21",
      "has_results": true,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-07-24T20:57:30.357Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Portland, Oregon + 3 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02404441"
    },
    {
      "nct_id": "NCT01214837",
      "title": "Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningococcal Disease",
        "Meningococcal Meningitis"
      ],
      "interventions": [
        {
          "name": "MenACWY-CRM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Routine Vaccines",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "55 Days to 89 Days"
      },
      "enrollment_count": 751,
      "start_date": "2010-10",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-07-24T20:57:30.357Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01214837"
    },
    {
      "nct_id": "NCT06662812",
      "title": "Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1665,
      "start_date": "2021-10-06",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-10-29",
      "last_synced_at": "2026-07-24T20:57:30.357Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06662812"
    },
    {
      "nct_id": "NCT00417261",
      "title": "Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ATF936",
          "type": "DRUG"
        },
        {
          "name": "AXT914",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "68 Years",
        "sex": "ALL",
        "summary": "18 Years to 68 Years"
      },
      "enrollment_count": 65,
      "start_date": "2006-11",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2008-06-23",
      "last_synced_at": "2026-07-24T20:57:30.357Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00417261"
    },
    {
      "nct_id": "NCT01190475",
      "title": "BGS649 Monotherapy in Moderate to Severe Endometriosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Active treatment with a high dose of BGS649",
          "type": "DRUG"
        },
        {
          "name": "Active treatment with a low dose of BGS649",
          "type": "DRUG"
        },
        {
          "name": "Placebo treatment to blind study",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mereo BioPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 6,
      "start_date": "2010-07",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2020-10-27",
      "last_synced_at": "2026-07-24T20:57:30.357Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01190475"
    },
    {
      "nct_id": "NCT02398500",
      "title": "Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-related Macular Degeneration (AMD)"
      ],
      "interventions": [
        {
          "name": "LMG324",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ranibizumab 0.5 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sham",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2015-07-22",
      "completion_date": "2016-05-20",
      "has_results": false,
      "last_update_posted_date": "2019-06-05",
      "last_synced_at": "2026-07-24T20:57:30.357Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02398500"
    },
    {
      "nct_id": "NCT05505292",
      "title": "Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Lifitegrast 5% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Lifitegrast Ophthalmic Solution Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "State University of New York College of Optometry",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2022-09-22",
      "completion_date": "2023-05-15",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-07-24T20:57:30.357Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05505292"
    },
    {
      "nct_id": "NCT00738387",
      "title": "A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ASA404",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 900,
      "start_date": "2008-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-12-24",
      "last_synced_at": "2026-07-24T20:57:30.357Z",
      "location_count": 88,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • Bentonville, Arkansas + 76 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00738387"
    }
  ]
}